GlassScriptPhysician profile
George G Miranda
NPI 1558545038
$18,034.27
in general payments reported to CMS, 2019-2025
90 companies · $3,495 in 2025
The $3,495 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,132 · 2020: $1,712 · 2021: $1,539 · 2022: $2,599 · 2023: $3,070 · 2024: $3,487 · 2025: $3,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,998 · Education: $53.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,998.38 |
| Education | $53.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,669.46 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $1,636.00 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,405.63 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $836.67 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $777.86 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $576.64 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $510.30 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $471.53 | 2019-2023 | Imbruvica |
| Abbvie INC. | $462.71 | 2019-2025 | |
| Daiichi Sankyo INC. | $426.09 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $417.39 | 2020-2025 | Fruzaqla, Iclusig, Alunbrig |
| Lilly USA, LLC | $405.99 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $389.84 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Genentech USA, INC. | $389.01 | 2019-2025 | Polivy, Tecentriq, Itovebi |
| Astellas Pharma US INC | $387.32 | 2019-2025 | Xtandi, Padcev, Vyloy |
Show all 90 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $342.89 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Eisai INC. | $323.72 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $312.83 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $299.44 | 2020-2025 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $285.36 | 2022-2025 | Libtayo |
| Seagen INC. | $282.54 | 2019-2023 | Adcetris, Padcev |
| Exelixis INC. | $267.29 | 2019-2025 | Cabometyx |
| Amgen INC. | $258.24 | 2019-2025 | Kyprolis, Blincyto, Lumakras |
| Beigene USA, INC. | $243.85 | 2020-2025 | Brukinsa |
| Pharmaessentia USA Corporation | $220.17 | 2022-2025 | Besremi |
| Blueprint Medicines Corporation | $215.00 | 2021-2025 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $201.41 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Aveo Pharmaceuticals, INC. | $194.78 | 2021-2025 | Fotivda |
| Genzyme Corporation | $186.98 | 2020-2024 | |
| Emd Serono, INC. | $182.04 | 2019-2023 | Bavencio |
| Deciphera Pharmaceuticals INC. | $164.21 | 2021-2024 | Qinlock |
| Puma Biotechnology, INC. | $157.74 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $141.91 | 2019-2023 | Xarelto |
| Gilead Sciences, INC. | $125.34 | 2021-2024 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $124.79 | 2020-2025 | Onivyde, Somatuline Depot |
| Kite Pharma, INC. | $120.18 | 2020-2024 | Yescarta |
| Array Biopharma INC | $117.07 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Sumitomo Pharma America, INC. | $113.35 | 2023-2025 | Orgovyx |
| Tersera Therapeutics LLC | $113.07 | 2020-2024 | Quzyttir |
| Alexion Pharmaceuticals, INC. | $110.83 | 2019-2025 | Ultomiris |
| Taiho Oncology, INC. | $109.15 | 2023-2025 | |
| Stemline Therapeutics INC. | $100.58 | 2019-2024 | Orserdu, Elzonris |
| Tempus Ai, INC | $88.07 | 2024 | |
| Genmab U.S., INC. | $82.82 | 2024-2025 | Epkinly |
| Beone Medicines USA, INC. | $82.75 | 2025 | Brukinsa, Tevimbra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.00 | 2020-2024 | Gilotrif |
| Sobi, INC | $78.95 | 2022-2025 | |
| Adc Therapeutics America, INC. | $76.70 | 2023-2025 | |
| Coherus Oncology, INC. | $69.35 | 2022-2025 | Loqtorzi, Udenyca |
| Myovant Sciences INC. | $68.75 | 2021-2022 | |
| Eusa Pharma (US) LLC | $66.76 | 2020-2022 | |
| Mirati Therapeutics, INC. | $64.66 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $62.55 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $58.97 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $48.67 | 2023-2025 | Givlaari |
| Mylan Institutional INC. | $47.77 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $47.71 | 2024-2025 | Sylvant, Enjaymo |
| Iovance Biotherapeutics, INC. | $46.63 | 2025 | Amtagvi |
| Octapharma USA, INC. | $46.51 | 2023 | Panzyga |
| Springworks Therapeutics, INC. | $45.95 | 2024-2025 | Ogsiveo |
| Agios Pharmaceuticals, INC. | $43.99 | 2023-2025 | Pyrukynd |
| Cti Biopharma Corp. | $43.19 | 2023 | Vonjo |
| Teva Pharmaceuticals USA, INC. | $42.32 | 2019-2020 | |
| Geron Corporation | $40.15 | 2024-2025 | Rytelo |
| Morphosys, US INC. | $39.10 | 2023 | Monjuvi |
| Ge Healthcare | $38.16 | 2025 | |
| Azurity Pharmaceuticals, INC. | $38.10 | 2025 | Danziten |
| Kyowa Kirin, INC. | $35.39 | 2019-2023 | Poteligeo |
| Acrotech Biopharma INC. | $34.15 | 2021-2022 | |
| Chiesi USA, INC. | $28.63 | 2024-2025 | Ferriprox |
| Immunogen, INC. | $27.93 | 2023 | Elahere |
| Progenics Pharmaceuticals, INC. | $25.96 | 2022 | |
| Dendreon Pharmaceuticals LLC | $25.07 | 2019 | |
| Legend Biotech USA INC. | $24.93 | 2025 | Carvykti |
| Tg Therapeutics, INC. | $24.02 | 2021 | |
| Spectrum Pharmaceuticals INC. | $23.71 | 2024 | Rolvedon |
| Amag Pharmaceuticals, INC. | $22.50 | 2021 | |
| Csl Behring | $21.44 | 2023 | Idelvion, Afstyla |
| Immunocore Limited | $21.01 | 2024 | Kimmtrak |
| Fennec Pharmaceuticals, INC. | $20.24 | 2025 | Fyarro |
| Apellis Pharmaceuticals, INC. | $20.08 | 2025 | Empaveli |
| Aurobindo Pharma USA, INC. | $19.81 | 2020 | |
| Tesaro, INC. | $19.07 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $18.54 | 2019 | |
| Clovis Oncology, INC. | $18.39 | 2020 | |
| Dova Pharmaceuticals | $17.58 | 2019 | |
| Foundation Medicine, INC. | $17.45 | 2023 | |
| Sanofi-Aventis U.S. LLC | $16.98 | 2020 | |
| Secura Bio, INC. | $13.34 | 2020 | |
| Sirtex Medical INC | $11.27 | 2020 |
Drugs and devices associated with these payments
Keytruda $1,102Enhertu $359Jakafi $282Imbruvica $266Calquence $236Kisqali $229Libtayo $229Reblozyl $222Lenvima $221Darzalex $215Tecvayli $215Xpovio $210Brukinsa $196Imfinzi $195Opdivo $185Orgovyx $163Epkinly $160Fotivda $152Jaypirca $150Monjuvi $144Lynparza $142Scemblix $136Ayvakit $131Opdualag $129Elahere $126Verzenio $123Adcetris $121Besremi $119Cabometyx $119Ojjaara $119Welireg $114Xtandi $112Lonsurf $109Inqovi $109Fruzaqla $106Rezlidhia $105Tavalisse $105Fabhalta $103Iclusig $103Mektovi $95.27Mekinist $93.45Tivdak $91.18Qinlock $90.81Somatuline Depot $89.16Onivyde $89.16Venclexta $83.58Pemazyre $81.65Sarclisa $81.27Braftovi $80.08Polivy $77.39Padcev $76.00Talvey $75.20Retevmo $73.50Nubeqa $72.33Elrexfio $70.68Bosulif $69.61Gilotrif $65.41Alunbrig $64.72Krazati $64.66Rybrevant $61.87Ultomiris $61.83Doptelet $60.59Zepzelca $58.97Orserdu $57.67Quzyttir $57.32Yescarta $55.50Lutathera $55.20Zynlonta $54.48Tecentriq $54.17Erleada $53.09Vanflyta $51.74Talzenna $49.99Givlaari $48.67Xalkori $48.43Lorbrena $48.43Paxlovid $46.90Tukysa $46.84Amtagvi $46.63Panzyga $46.51Besponsa $46.04Ogsiveo $45.95Jemperli $44.57Pyrukynd $43.99Vonjo $43.19Rytelo $40.15Gavreto $39.73Kyprolis $38.33Danziten $38.10Tibsovo $38.09Idhifa $38.09Bavencio $33.36Tagrisso $32.69Piqray $32.41Vyloy $32.39Cuvitru $30.07Zejula $29.68Ferriprox $28.63Stivarga $28.30Vitrakvi $28.30Nerlynx $28.11
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.